Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains [Seeking Alpha]
Galectin Therapeutics Inc. (GALT)
Last galectin therapeutics inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.galectintherapeutics.com/investor-relations
Company Research
Source: Seeking Alpha
These results were, on paper, supportive antifibrotic biomarker trends. That's why GALT is now pushing additional subgroup/biomarker analyses. This means they'll do a longer follow-up, but a pivotal trial design and FDA acceptance of endpoints remain unresolved. GALT has now become overwhelmingly concentrated in Belapectin for MASH cirrhosis as its main value driver. Yet, its cash runway already looks tight, and Belapectin's pathway going forward seems somewhat uncertain. Thus, I feel a neutral rating at these levels is justified. Natali_Mis/iStock via Getty Images Galectin Therapeutics Inc. ( GALT ) is a clinical-stage biotechnology company that develops Belapectin, a galectin-3 inhibitor aimed at treating advanced fibrotic liver disease and selected oncology indications. Unfortunately, their NAVIGATE Phase 2b/3 trial failed to meet its primary endpoint, but This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in a
Show less
Read more
Impact Snapshot
Event Time:
GALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GALT alerts
High impacting Galectin Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GALT
News
- Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line [Yahoo! Finance]Yahoo! Finance
- Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 [Yahoo! Finance]Yahoo! Finance
- Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027GlobeNewswire
- Galectin Therapeutics (NASDAQ:GALT) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data [Seeking Alpha]Seeking Alpha
GALT
Analyst Actions
- 12/17/25 - HC Wainwright
GALT
Sec Filings
- 12/23/25 - Form 4/A
- 12/23/25 - Form 4/A
- 12/23/25 - Form 4
- GALT's page on the SEC website